Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3683 results about "Moiety" patented technology

In organic chemistry, a moiety (/ˈmɔɪəti/) is a part of a molecule which is typically given a name as it can be found within other kinds of molecules as well. The term moiety should be reserved to describe the larger characteristic parts of molecules and not used to describe smaller functional groups, which are made up of atoms that participate in similar chemical reactions in most molecules that contain them. In some instances moieties may be composed of yet smaller moieties and functional groups.

Methods and compositions for targeted protein degradation

Provided are PROTACs comprised of a targeting moiety designed to bind KRAS (G12D / C / V) linked to a degrader-directing moiety designed to bind an E3 ubiquitin-ligase. Pharmaceutical compositions comprising the disclosed PROTACs and their use in treating cancer and related conditions are also provided.
Owner:RANOK THERAPEUTICS (HANGZHOU) CO LTD +9

Radiation-sensitive composition, pattern forming method, and onium salt compound

Provided are: a radiation-sensitive composition capable of exhibiting sensitivity, LWR performance and CDU performance each at a sufficient level when forming a resist pattern, and having good storage stability; a pattern forming method; and an onium salt compound. This radiation-sensitive composition contains: an onium salt compound represented by formula (1); a polymer containing a structural unit (I) having an acid-dissociable group; and a solvent. (In formula (1), W is a cyclic structure having 3-40 ring members and composed with two carbon atoms. The formula between carbon-carbon atoms represents a single or double bond. A is a group represented by formula (A-1), a group represented by formula (A-2), a group represented by formula (A-3), a group represented by formula (A-4), a group represented by formula (A-5), a group represented by formula (A-6), or a group represented by formula (A-7). (In formulae (A-3) and (A-4), RA1 and RA2 are each independently a monovalent hydrocarbon group having 1-20 carbon atoms. * is a bond to a carbon atom.) R1 is a monovalent organic group having 1-20 carbon atoms, a cyano group, a nitro group, a carboxy group, a hydroxy group, an amino group, a halogen atom or a thiol group. In a case where multiple R1 moieties are present, the multiple R1 moieties may be the same as, or different from, each other. m1 is an integer between 0 and 4. Z+ is a monovalent radiation-sensitive onium cation.)
Owner:JSR CORPORATION

Lipid nanoparticle formulations and compositions

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Spatially identifying nucleic acids that interact with proteins

PendingUS20250230498A1MoietyGenomic clone
Provided herein are methods, compositions, and kits to spatially detect a polypeptide-nucleic acid complex or a protein-nucleic acid complex in a biological sample. For example, such methods can include contacting binding agents with a biological sample, wherein a binding agent specifically binds a polypeptide of a polypeptide-nucleic acid complex; aligning the biological sample with a substrate comprising a plurality of capture moieties, wherein the binding agent interacts with a capture moiety; releasing the nucleic acid of the binding agent-polypeptide-nucleic acid complex; hybridizing the released nucleic acid to a capture domain of a capture probe on an array; and using determined sequences of a spatial barcode in the capture probe and the released nucleic acid to determine the location of the released nucleic acid in the biological sample, thereby determining the location of the polypeptide-nucleic acid complex in the biological sample.
Owner:10X GENOMICS INC

Ionizable cationic lipids with conserved spacing and lipid nanoparticles

PCT designated stage expiredWO2025076113A1Powder deliveryOrganic chemistryNanoparticleMoiety
Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids, and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for delivering nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is a LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Owner:CAPSTAN THERAPEUTICS INC

Lipid nanoparticle formulations and compositions

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Multifunctional molecules that bind to calreticulin and uses thereof

Multifunctional molecules that include i) an antigen binding domain that binds to a calreticulin mutant protein; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or a modulator of a cytokine molecule; and / or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
Owner:MARENGO THERAPEUTICS INC

Multispecific molecules binding to TCR and uses thereof

Provides herein are multifunctional polypeptide molecules comprising T cell receptor variable alpha-binding moieties, T cell receptor variable beta-binding moieties, TAA-binding moieties, and / or cytokines, and methods of treating conditions or diseases in a subject using the same.
Owner:MARENGO THERAPEUTICS INC

Antibody-drug conjugates employing novel linker-payload systems for enhanced targeting of cancer-associated antigens

An antibody-drug conjugate (ADC) is provided and comprises an antibody which binds to sialyl Tn (STn) or a glycan terminated by an alpha 2,6-linked sialic acid, conjugated to a drug via a linker, wherein the linker comprises a cleavable linker, and the drug comprises a growth inhibitory agent which is exatecan, deruxtecan, or a derivative thereof. The antibody-drug conjugate (ADC) of the invention comprises a linker cleavable by glucuronidase, for examples the linker comprises a β-glucuronide moiety, such as shown in formula I: Formula (I). The antibody-drug conjugate (ADC) comprises a linker which is linked to, or is modified to link to, the drug via a carbamate linkage, or a linker which is linked to, or is modified to link to, the drug via a quaternary ammonium salt linkage. The antibody-drug conjugate (ADC) may comprise a linker which is PEGylated with a group comprising polyethylene glycol (PEG). Novel linkers for use in ADCs are also described.
Owner:BIONTECH SE

Optically detectable label and marker

An optically detectable label (102, 500) is provided comprising a nucleic acid backbone (108, 504) comprising multiple attachment positions (306, 308, 506a, 506b, 506c, 506d) including at least a first attachment position and a second attachment position. The optically detectable label (102, 500) further comprises multiple labelling moieties (106a, 106b, 106c, 106d, 106e, 310, 312, 502a, 502b, 502c, 502d), including at least a first labelling moiety and a second labelling moiety, each labelling moiety (106a, 106b, 106c, 106d, 106e, 310, 312, 502a, 502b, 502c, 502d) attached to a different one of the attachment positions (306, 308, 506a, 506b, 506c, 506d) of the nucleic acid backbone (108, 504). The first labelling moiety and the second labelling moiety are configured to form an energy transfer donor and acceptor pair. Further, the nucleic acid backbone (108, 504) has at least a first spatial state (300, 500a) and a second spatial state (322, 500b), wherein in the first spatial state the attachment position to which the first labelling moiety and the attachment position to which the second labelling moiety are attached to, are in proximity in order to enable an energy transfer between the first labelling moiety and the second labelling moiety. Moreover, the nucleic acid backbone (108, 504) is in the first spatial state (300, 500a) when a first staple strand (302, 510, 512) is bound to the nucleic acid backbone (108, 504). In further aspects, a marker (100) comprising the optically detectable label (102, 500) is provided and a method for analysing a biological sample.
Owner:LEICA MICROSYSTEMS CMS GMBH

Organic electroluminescent materials and devices

A compound comprising a first ligand LA of Formula I,is provided, where: each of moiety A and moiety B is a monocyclic ring or a polycyclic fused ring system; each of X1 to X4 and Z1 and Z2 is C or N; K1 and K2 are each a direct bond or a linker; L1 is a direct bond or an organic linker; each Rα, Rβ, RA and RB is hydrogen or a General Substituent defined herein; and at least one RA or one RB comprises R*, where R* is an alkyl group, a silyl group, a germyl group, or a combination thereof. Formulations, OLEDs, and consumer products containing the compound are also provided.
Owner:UNIVERSAL DISPLAY CORP

Antibody-drug conjugates

An antigen-binding molecule that binds to a target antigen, comprising (i) a target antigen-binding moiety, and (ii) at least one linker-payload moiety, wherein the antigen-binding molecule comprises (a) DNA damage response (DDR) inhibitor moiety, and (b) a DNA topoisomerase I (TOP1) inhibitor moiety.
Owner:HUMMINGBIRD BIOSCIENCE HOLDINGS PTE LTD +1

Lipid nanoparticle formulations and compositions

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Il-18 fusion proteins and methods of producing il-18

Fusion proteins are provided that consist of essential elements such as one or more proteins / polypeptides capable of transporting into the endoplasmic reticulum (ER) and fragments or variants of interleukin 18 (IL-18) or IL-18. The proteins / polypeptides capable of transporting into the ER include, but are not limited to, immune globular proteins (e.g., Fc regions, VHH antibodies, and scFv), and globular proteins (e.g., serum albumin). In some embodiments, the IL-18 may be a pro-IL-18 similar to a natural precursor cytokine, wherein IL-18 is fused to the C-terminus of a propeptide or a propeptide variant thereof. In some embodiments, the fusion protein may further comprise a cleavable peptide linker.
Owner:FUSE BIOTHERAPEUTICS INC

Organic electroluminescent materials and devices

A compound comprising a first ligand LA of Formula I,is provided. In Formula I, moiety A is a monocyclic ring or a polycyclic fused ring system, moiety B is a polycyclic fused ring system; each of Z1 to Z4 is C or N; each of K1 and K2 is a direct bond or a linker; at least one RB or RA comprises,where T is B, C, N, Si, Ge, Bi, or P; V is a direct bond or a linker; R1 and R2 are present, and R3 is optionally present; each substituent is independently hydrogen or a General Substituent defined herein; and at least two of R1, R2, and R3 has two or more carbon atoms. Formulations, OLEDs, and consumer products containing the compound are also provided.
Owner:UNIVERSAL DISPLAY CORP

Her2-binding molecules

An antigen-binding molecule that binds to HER2, comprising (i) a HER2-binding moiety, and (ii) at least one linker-payload moiety, wherein the antigen-binding molecule comprises (a) DNA damage response (DDR) inhibitor moiety, and (b) a DNA topoisomerase I (TOP1) inhibitor moiety.
Owner:HUMMINGBIRD BIOSCIENCE HOLDINGS PTE LTD +1

Organic electroluminescent materials and devices

A compound of formula Ir(LA)x(LB)y(LC)z, where x and y are 1 or 2; z is 0 or 1; and x+y+z=3. In the compound, LA comprises Formula I,ligand LB comprises Formula II,and ligand LC is a bidentate ligand. In Formulas I and II, moiety A is a monocyclic ring or a polycyclic fused ring system; each of X1 to X14 is C or N; Y is a linking group; each R1-R2, R, R′, and RA-RE is hydrogen or a General Substituent defined herein; at least one of R1 and R2 is a tertiary alkyl group; and (1) at least one pair of RB or RC substituents are joined or fused to form a ring, or (2) at least one RC or RB comprises an electron-withdrawing group other than nitrile, or (3) X11 is N, R1 is a tertiary alkyl group. Formulations, OLEDs, and consumer products containing the compound are also provided.
Owner:UNIVERSAL DISPLAY CORP

Heterobifunctional compounds and their use in treating disease

The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from GSPT1, Cyclin K, RBM23, RBM39, IKZF1, IKZF3, PLK1, CDK4 or CK1alpha which is linked to a moiety that binds to a target protein selected from KRAS, HER2, EGFR, androgen receptor protein, estrogen receptor protein, ALK, IDH1, FLT3, FGFR1, FGFR4, FGFR2, FGFR3, ERK1, ERK2, FGR, HER3 or HER4. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
Owner:HALDA THERAPEUTICS OPCO INC

Organic electroluminescent materials and devices

A compound of Formula I,is provided. In Formula I, moiety A is a monocyclic ring or a polycyclic fused ring system; each of X1 to X2 and Z1 to Z3 is independently C or N; Y1 is C, N, O, S, Se, P, or As; K is a direct bond or a linker; each of A1 and A2 is C, Si, N, P, or As; each of L1, L2, and L3 is absent, a direct bond, or a linker; at least one of L1 to L4 is present; when L3 is present, X11 is C, whereas if L3 is absent, X11 is C or N; M is Pt or Pd; each R1, R2, RA, RB, RC, RD, Rα, and Rβ is hydrogen or a General Substituent defined herein and R* is a General Substituent defined herein. Formulations, OLEDs, and consumer products containing the compound are also provided.
Owner:UNIVERSAL DISPLAY CORP

Isoindolinone-glutarimide antibody conjugates, and uses thereof

The invention provides antibody conjugates of Formula I comprising an antibody linked by conjugation to one or more isoindolinone-glutarimide moieties. The invention also provides isoindolinone-glutarimide derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the antibody conjugates through a linker or linking moiety. The invention further provides methods of treating diseases and disorders such as cancer with the antibody conjugates.
Owner:FIREFLY BIO INC

Multifunctional molecules binding to TCR and uses thereof

Provides herein are multifunctional polypeptide molecules comprising T cell receptor variable alpha-binding moieties and cytokines and methods of treating conditions or diseases in a subject using the same.
Owner:MARENGO THERAPEUTICS INC

Multifunctional organosilicon compound and related methods, compounds, and compositions

A multifunctional organosilicon compound is provided which has the general formula XSi([OSiR2]p-0-SiR2Y)a(R1)3-a— ln the formula, X is selected from H and ethylenically un saturated moieties; each Y independently comprises a functional moiety selected from alkoxysilyl moieties, acryloxy moieties, and epoxide moieties; each R is an independently selected hydrocarbyl group; each R1 is an independently selected hydrocarbyl group; subscript a is 1, 2, or 3; and each subscript b is independently 0, 1, or 2. A method of preparing the multifunctional organosilicon compound is also provided. The method comprises reacting (A) an organosilanol compound and (B) a silane compound having at least two hydrolysable groups. A functionalized siloxane compound prepared from the multifunctional organosilicon compound, a method of preparing the functionalized siloxane compound, and an adhesive comprising the functionalized siloxane compound are also provided.
Owner:DOW SILICONES CORP

Selective histone deacylase 8 (HDAC8) degrading agents and methods of use thereof

The present disclosure relates to compounds, compositions and methods for treating diseases or conditions mediated by aberrant histone deacetylase 8 (HDAC8) activity. In some embodiments, the disclosed compounds comprise an HDAC8 targeting ligand TL moiety covalently linked to a degradation determinant moiety that recruits E3 ubiquitin ligase to HDAC8. In some embodiments, the degradation determinant can bind to an E3 ligase, which is a von Hippel-Lindau (VHL) tumor suppressor, and the E3 ligase can bind to an E3 ligase, which is a Von Hippel-Lindau (VHL) tumor suppressor.
Owner:DANA FARBER CANCER INSTITUTE INC

Heterobifunctional compounds and their use in treating disease

The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDKI, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC which is linked to a moiety that binds to a target protein selected from KRAS, HER2 or EGFR. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
Owner:HALDA THERAPEUTICS OPCO INC

Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy

The present application relates to a composition comprising (a) at least one immune checkpoint inhibitor and (b) at least one conjugate, wherein said conjugate is comprising (i) a target binding moiety, (ii) at least one amatoxin, and (iii) optionally at least one linker connecting said target binding moiety with said at least one amatoxin. The present application further relates to said composition for use in treating a patient having a cancer, and to a pharmaceutical formulation comprising said composition and additional excipients, as well as to methods of producing and using said composition (FIG. 1).
Owner:HEIDELBERG PHARMA RES GMBH

Polymerase-conjugate binding stabilization

The present disclosure relates in some aspects to methods, systems, and kits for sequencing a template nucleic acid molecule, where the methods comprise: (i) contacting a priming strand bound to the template nucleic acid molecule with a first plurality of nucleotide molecules and a polymerase coupled to a heterologous polynucleotide-binding moiety to form a complex comprising a 3′ terminus of the priming strand, the template nucleic acid molecule, the polymerase, and a nucleotide molecule of the first plurality of nucleotide molecules, wherein the polynucleotide-binding moiety enhances stability of the complex, and wherein the priming strand comprises a reversibly-terminated nucleotide at its 3′ end such that the nucleotide molecule of the transient complex is not incorporated; and (ii) detecting a presence of the nucleotide molecule in the complex to identify a complementary nucleotide in the template nucleic acid molecule.
Owner:10X GENOMICS INC

Acrylate-functional branched organosilicon compound, method of preparing same, and copolymer formed therewith

A method of preparing an acrylate-functional branched organosilicon compound (“compound”) is provided, and comprises reacting (A) a branched organosilicon compound and (B) an acrylate compound in the presence of (C) a catalyst, wherein component (A) has the general formula X—Si(R1)3, where X comprises a halogen-functional moiety and each R1 is selected from R and —OSi(R4)3, with the proviso that at least one R1 is —OSi(R4)3; each R4 is selected from R, —OSi(R5)3, and —[OSiR2]mOSiR3; each R5 is selected from R, —OSi(R6)3, and —[OSiR2]mOSiR3; each R6 is selected from R and —[OSiR2]mOSiR3; each R is an independently selected hydrocarbyl group; and 0≤m≤100; with the proviso that at least one of R4, R5 and R6 is —[OSiR2]mOSiR3. The compound prepared by the method, a copolymer comprising the reaction product of the compound and a second compound, a method of forming the copolymer, and a composition comprising the copolymer are each also provided.
Owner:DOW SILICONES CORP

Antibody-oligonucleotide conjugate

The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention for use in the treatment or prophylaxis of a cancer.
Owner:SAPREME TECH BV